Imitex

There are a range of inherited muscle degenerative diseases that characterised by muscle wastage and atrophy. Of particular interest are Facioscapulohumeral muscular dystrophy (FSHD), Duchenne muscular dystrophy (DMD) and Kennedy’s disease (SBMA). These, and other similar conditions are characterised by ongoing muscle wastage eventually leading to tremors, loss of mobility, and often respiratory failure leading to death. Imitex’s approach offers the promise of ameliorating muscle wastage, enabling improvements to musculo-skeletal tone, and associated secondary (metabolic pathways).

Sarcopenia is age-related loss of skeletal muscle mass and function, leading to physical disability, poor quality of life and eventually death. Sarcopenia negatively impacts many seniors, and can lead to loss of mobility, increased risk of falls and an associated loss of independence.  Whilst the incidence and societal cost of sarcopenia are well understood, there are currently no therapeutics approved to treat this debilitating condition. Imitex’s approach, based on a detailed understanding of the molecular processes that drive muscle strengthening, offer new solutions to this condition.